{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alirocumab+SAR236553+%28REGN727%29", "query": { "intervention": "Alirocumab SAR236553 (REGN727)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 34, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alirocumab+SAR236553+%28REGN727%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-10T16:24:10.130Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01448239", "title": "Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "alirocumab SAR236553 (REGN727)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2011-02", "completion_date": "2011-05", "has_results": false, "last_update_posted_date": "2013-06-28", "last_synced_at": "2026-10-10T16:24:10.130Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01448239" }, { "nct_id": "NCT02585778", "title": "Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolaemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Lipid-Modifying Therapy (LMT)", "type": "DRUG" }, { "name": "Antihyperglycemic Drug", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 517, "start_date": "2015-10-23", "completion_date": "2017-04-03", "has_results": true, "last_update_posted_date": "2018-05-17", "last_synced_at": "2026-10-10T16:24:10.130Z", "location_count": 29, "location_summary": "Encino, California • Fresno, California • Oakland, California + 25 more", "locations": [ { "city": "Encino", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Loveland", "state": "Colorado" }, { "city": "Atlantis", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02585778" }, { "nct_id": "NCT01730053", "title": "Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 305, "start_date": "2012-11-30", "completion_date": "2014-05-31", "has_results": true, "last_update_posted_date": "2020-04-07", "last_synced_at": "2026-10-10T16:24:10.130Z", "location_count": 54, "location_summary": "Chandler, Arizona • Tucson, Arizona • Anaheim, California + 51 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fair Oaks", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01730053" }, { "nct_id": "NCT01074372", "title": "Ascending Dose Study of the Safety and Tolerability of REGN727 (SAR236553) in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "REGN727", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 32, "start_date": "2010-03", "completion_date": "2010-11", "has_results": false, "last_update_posted_date": "2015-01-27", "last_synced_at": "2026-10-10T16:24:10.130Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01074372" }, { "nct_id": "NCT01644188", "title": "Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo (for alirocumab)", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Placebo (for ezetimibe)", "type": "DRUG" }, { "name": "Lipid Modifying Therapy (LMT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 720, "start_date": "2012-08", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2016-08-04", "last_synced_at": "2026-10-10T16:24:10.130Z", "location_count": 58, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01644188" }, { "nct_id": "NCT01161082", "title": "Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "REGN727(SAR236553)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 72, "start_date": "2010-06", "completion_date": "2011-05", "has_results": false, "last_update_posted_date": "2015-01-27", "last_synced_at": "2026-10-10T16:24:10.130Z", "location_count": 2, "location_summary": "Cincinnati, Ohio • Knoxville, Tennessee", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01161082" }, { "nct_id": "NCT01730040", "title": "Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 355, "start_date": "2012-10", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2015-08-31", "last_synced_at": "2026-10-10T16:24:10.130Z", "location_count": 56, "location_summary": "Mobile, Alabama • Chandler, Arizona • Tucson, Arizona + 53 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01730040" }, { "nct_id": "NCT01617655", "title": "Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolaemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo (for alirocumab)", "type": "DRUG" }, { "name": "Lipid Modifying Therapy (LMT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2012-06", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2016-10-04", "last_synced_at": "2026-10-10T16:24:10.130Z", "location_count": 14, "location_summary": "Bell Gardens, California • Newport Beach, California • Northridge, California + 8 more", "locations": [ { "city": "Bell Gardens", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01617655" }, { "nct_id": "NCT02642159", "title": "Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Dyslipidemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Statins", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Fenofibrate", "type": "DRUG" }, { "name": "Nicotinic acid", "type": "DRUG" }, { "name": "Omega-3 fatty acids", "type": "DRUG" }, { "name": "Antihyperglycemic Drug", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 413, "start_date": "2016-03-15", "completion_date": "2017-05-15", "has_results": true, "last_update_posted_date": "2018-05-01", "last_synced_at": "2026-10-10T16:24:10.130Z", "location_count": 57, "location_summary": "Little Rock, Arkansas • Fresno, California • Huntington Beach, California + 51 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fresno", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02642159" }, { "nct_id": "NCT07477704", "title": "A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 420, "start_date": "2026-06-17", "completion_date": "2027-02-23", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-10T16:24:10.130Z", "location_count": 34, "location_summary": "Anniston, Alabama • Cullman, Alabama • Anaheim, California + 30 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Cullman", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Walnut Creek", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07477704" } ] }